Nonstandard drugs and feasible new interventions for autoimmune hepatitis: Part I

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 5, 2012, Pages 337-350

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Nonstandard drugs; Rescue agents; Salvage therapy

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; TIOGUANINE;

ADVERSE OUTCOME; AKINESIA; ARTICLE; ATAXIA; AUTOIMMUNE HEPATITIS; BLINDNESS; BONE MARROW SUPPRESSION; BRAIN EDEMA; CELL PROLIFERATION; CENTRAL PONTINE MYELINOLYSIS; CLEFT FACE; COLOBOMA; CONFUSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; EDEMA; GINGIVA HYPERPLASIA; GINGIVITIS; HALLUCINATION; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTELORISM; HYPERTENSION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DISEASE; LUNG ALVEOLITIS; LUNG HEMORRHAGE; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MICROGNATHIA; MICROTIA; MITRAL VALVE ATRESIA; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRURITUS; PSYCHOSIS; PULMONARY VALVE STENOSIS; SEIZURE; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

ANIMALS; BUDESONIDE; CYCLOSPORINE; DRUG DISCOVERY; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSION; MYCOPHENOLIC ACID; TACROLIMUS; THIOGUANINE;

EID: 84866397703     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812803251006     Document Type: Article

References (223)

1. Czaja, A.J. Current and future treatments of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol., 2009, 3 (3), 269-291.
2. Manns, M.P.; Czaja, A.J.; Gorham, J.D.; Krawitt, E.L.; Mieli-Vergani, G.; Vergani, D.; Vierling, J.M. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51 (6), 2193-2213.
3. Strassburg, C.P.; Manns, M.P. Therapy of autoimmune hepatitis. Best Pract. Res. Clin. Gastroenterol., 2011, 25 (6), 673-687.
4. Cook, G.C.; Mulligan, R.; Sherlock, S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med., 1971, 40 (158), 159-185.
5. Soloway, R.D.; Summerskill, W.H.; Baggenstoss, A.H.; Geall, M.G.; Gitnick, G.L.; Elveback, I.R.; Schoenfield, L.J. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology, 1972, 63 (5), 820-833.
6. Murray-Lyon, I.M.; Stern, R.B.; Williams, R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet, 1973, 1 (7806), 735-737.
7. Czaja, A.J. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol. Dietol., 2005, 51 (4), 313-333.
8. Czaja, A.J.; Bayraktar, Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J. Gastroenterol., 2009, 15 (19), 2314-2328.
9. Czaja, A.J. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin. Liver Dis., 2009, 29 (3), 315-330.
10. Czaja, A.J. Autoimmune hepatitis in special patient populations. Best Pract. Res. Clin. Gastroenterol., 2011, 25 (6), 689-700.
11. Nikias, G.A.; Batts, K.P.; Czaja, A.J. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J. Hepatol., 1994, 21 (5), 866-871.
12. Czaja, A.J. Difficult treatment decisions in autoimmune hepatitis. World J. Gastroenterol., 2010, 16 (8), 934-947.
13. Czaja, A.J. Autoantibody-negative autoimmune hepatitis. Dig. Dis. Sci., 2012, 57 (3), 610-624.
14. Czaja, A.J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology, 1998, 28 (2), 360-365.
15. Ben-Ari, Z.; Czaja, A.J. Autoimmune hepatitis and its variant syndromes. Gut, 2001, 49 (4), 589-594.
16. Montano-Loza, A.J.; Carpenter, H.A.; Czaja, A.J. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J. Clin. Gastroenterol., 2008, 42 (9), 1047-1053.
17. Gonzalez-Koch, A.; Czaja, A.J.; Carpenter, H.A.; Roberts, S.K.; Charlton, M.R.; Porayko, M.K.; Rosen, C.B.; Wiesner, R.H. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl., 2001, 7 (4), 302-310.
18. Czaja, A.J. Recurrent autoimmune hepatitis after liver transplantation. Ann. Gastroenterol. Hepatol., 2010, 1 (1), 79-89.
19. Liberal, R.; Longhi, M.S.; Grant, C.R.; Mieli-Vergani, G.; Vergani, D. Autoimmune hepatitis after liver transplantation. Clin. Gastroenterol. Hepatol., 2012, 10 (4), 346-353.
20. Czaja, A.J. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig. Dis. Sci., 2012, [Epub ahead of print].
21. Czaja, A.J. Cryptogenic chronic hepatitis and its changing guise in adults. Dig. Dis. Sci., 2011, 56 (12), 3421-3438.
22. Czaja, A.J. Advances in the current treatment of autoimmune hepatitis. Dig. Dis. Sci., 2012, [Epub ahead of print 2012 April 3; DOI:10.1007/s10620-012-2151-2].
23. Alvarez, F.; Berg, P.A.; Bianchi, F.B.; Bianchi, L.; Burroughs, A.K.; Cancado, E.L.; Chapman, R.W.; Cooksley, W.G.; Czaja, A.J.; Desmet, V.J.; Donaldson, P.T.; Eddleston, A.L.; Fainboim, L.; Heathcote, J.; Homberg, J.C.; Hoofnagle, J.H.; Kakumu, S.; Krawitt, E.L.; Mackay, I.R.; MacSween, R.N.; Maddrey, W.C.; Manns, M.P.; McFarlane, I.G.; Meyer zum Buschenfelde, K.H.; Zeniya, M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol., 1999, 31 (5), 929-938.
24. Heneghan, M.A.; Al-Chalabi, T.; McFarlane, I.G. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin. Pharmacother., 2006, 7 (2), 145-156.
25. Czaja, A.J.; Rakela, J.; Ludwig, J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology, 1988, 95 (2), 448-453.
26. Kanzler, S.; Lohr, H.; Gerken, G.; Galle, P.R.; Lohse, A.W. Longterm management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z. Gastroenterol., 2001, 39 (5), 339-341, 344-338.
27. Czaja, A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol., 2009, 51 (1), 161-167.
28. Czaja, A.J.; Ammon, H.V.; Summerskill, W.H. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology, 1980, 78 (3), 518-523.
29. Hegarty, J.E.; Nouri Aria, K.T.; Portmann, B.; Eddleston, A.L.; Williams, R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology, 1983, 3 (5), 685-689.
30. Czaja, A.J.; Menon, K.V.; Carpenter, H.A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology, 2002, 35 (4), 890-897.
31. Montano-Loza, A.J.; Carpenter, H.A.; Czaja, A.J. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int., 2007, 27 (4), 507-515.
32. Czaja, A.J. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig. Dis. Sci., 2010, 55 (6), 1761-1769.
33. Czaja, A.J.; Manns, M.P. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology, 2010, 139 (1), 58-72.
34. Manns, M.P. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology, 2011, 140 (7), 1874-1876.
35. Montano-Loza, A.J.; Carpenter, H.A.; Czaja, A.J. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology, 2007, 46 (4), 1138-1145.
36. Czaja, A.J. Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf., 2008, 7 (3), 319-333.
37. Czaja, A.J.; Davis, G.L.; Ludwig, J.; Taswell, H.F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology, 1984, 4 (4), 622-627.
38. Czaja, A.J.; Ludwig, J.; Baggenstoss, A.H.; Wolf, A. Corticosteroidtreated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N. Engl. J. Med., 1981, 304 (1), 5-9.
39. Czaja, A.J. Autoimmune hepatitis: focusing on treatments other than steroids. Can. J. Gastroenterol., 2012, [in press].
40. Czaja, A.J. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig. Dis. Sci., 2010, 55 (10), 2712-2726.
41. Czaja, A.J. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr. Pharm. Des., 2011, 17 (29), 3120-3140.
42. Czaja, A.J. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev. Gastroenterol. Hepatol., 2007, 1 (1), 113-128.
43. Czaja, A.J.; Beaver, S.J.; Shiels, M.T. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology, 1987, 92 (1), 215-219.
44. Czock, D.; Keller, F.; Rasche, F.M.; Haussler, U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet., 2005, 44 (1), 61-98.
45. Uribe, M.; Summerskill, W.H.; Go, V.L. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin. Pharmacokinet., 1982, 7 (5), 452-459.
46. Garg, V.; Jusko, W.J. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm. Drug Dispos., 1994, 15 (2), 163-172.
47. Uribe, M.; Schalm, S.W.; Summerskill, W.H.; Go, V.L. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut, 1978, 19 (12), 1131-1135.
48. Uribe, M.; Go, V.L. Corticosteroid pharmacokinetics in liver disease. Clin. Pharmacokinet., 1979, 4 (3), 233-240.
49. Schalm, S.W.; Summerskill, W.H.; Go, V.L. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology, 1977, 72 (5 Pt 1), 910-913.
50. Brattsand, R.; Linden, M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment. Pharmacol. Ther., 1996, 10 (Suppl 2), 81-90; discussion 91-82.
51. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol., 2000, 109 (1), 16-22.
52. Almawi, W.Y.; Beyhum, H.N.; Rahme, A.A.; Rieder, M.J. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol., 1996, 60 (5), 563-572.
53. Almawi, W.Y. Molecular mechanisms of glucocorticoid effects. Mod. Asp. Immunobiol., 2001, 2, 78-82.
54. Czaja, A.J.; Wang, K.K.; Shiels, M.T.; Katzmann, J.A. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J. Hepatol., 1993, 17 (2), 180-186.
55. Siekierka, J.J.; Hung, S.H.; Poe, M.; Lin, C.S.; Sigal, N.H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature, 1989, 341 (6244), 755-757.
56. Liu, J.; Farmer, J.D., Jr.; Lane, W.S.; Friedman, J.; Weissman, I.; Schreiber, S.L. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell, 1991, 66 (4), 807-815.
57. Iwasaki, K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab. Pharmacokinet., 2007, 22 (5), 328-335.
58. Martinez-Martinez, S.; Redondo, J.M. Inhibitors of the calcineurin/NFAT pathway. Curr. Med. Chem., 2004, 11 (8), 997-1007.
59. Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol., 2005, 5 (6), 472-484.
60. Hollander, G.A.; Bierer, B.E.; Burakoff, S.J. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. Transfus. Sci., 1994, 15 (3), 207-220.
61. Akhlaghi, F.; Trull, A.K. Distribution of cyclosporin in organ transplant recipients. Clin. Pharmacokinet., 2002, 41 (9), 615-637.
62. Jorgensen, K.A.; Koefoed-Nielsen, P.B.; Karamperis, N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand. J. Immunol., 2003, 57 (2), 93-98.
63. Czaja, A.J. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl., 2002, 8 (6), 505-513.
64. Hess, A.D.; Fischer, A.C.; Horwitz, L.R.; Laulis, M.K. Cyclosporineinduced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression. Transplant. Proc., 1993, 25 (5), 2811-2813.
65. Mistilis, S.P.; Vickers, C.R.; Darroch, M.H.; McCarthy, S.W. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med. J. Aust., 1985, 143 (10), 463-465.
66. Van Thiel, D.H.; Wright, H.; Carroll, P.; Abu-Elmagd, K.; Rodriguez-Rilo, H.; McMichael, J.; Irish, W.; Starzl, T.E. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am. J. Gastroenterol., 1995, 90 (5), 771-776.
67. Faulds, D.; Goa, K.L.; Benfield, P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 1993, 45 (6), 953-1040.
68. de Groen, P.C.; Aksamit, A.J.; Rakela, J.; Forbes, G.S.; Krom, R.A. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N. Eng. J. Med., 1987, 317 (14), 861-866.
69. Bechstein, W.O. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int., 2000, 13 (5), 313-326.
70. Serkova, N.J.; Christians, U.; Benet, L.Z. Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv., 2004, 4 (2), 97-107.
71. Liberal, R.; Longhi, M.S.; Grant, C.R.; Mieli-Vergani, G.; Vergani, D. Autoimmune Hepatitis after Liver Transplantation. Clin. Gastroenterol. Hepatol., 2011.
72. Lohse, A.W.; Weiler-Norman, C.; Burdelski, M. De novo autoimmune hepatitis after liver transplantation. Hepatol. Res., 2007, 37 (Suppl 3), S462.
73. Summerskill, W.H.; Korman, M.G.; Ammon, H.V.; Baggenstoss, A.H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut, 1975, 16 (11), 876-883.
74. Chan, G.L.; Erdmann, G.R.; Gruber, S.A.; Matas, A.J.; Canafax, D.M. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol., 1990, 30 (4), 358-363.
75. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol., 1992, 43 (4), 329-339.
76. Allison, A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 2000, 47 (2-3), 63-83.
77. Cara, C.J.; Pena, A.S.; Sans, M.; Rodrigo, L.; Guerrero-Esteo, M.; Hinojosa, J.; Garcia-Paredes, J.; Guijarro, L.G. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med. Sci. Monit., 2004, 10 (11), RA247-254.
78. Atreya, I.; Neurath, M.F. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev. Gastroenterol. Hepatol., 2008, 2 (1), 23-34.
79. Stellon, A.J.; Keating, J.J.; Johnson, P.J.; McFarlane, I.G.; Williams, R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology, 1988, 8 (4), 781-784.
80. Johnson, P.J.; McFarlane, I.G.; Williams, R. Azathioprine for longterm maintenance of remission in autoimmune hepatitis. N. Engl. J. Med., 1995, 333 (15), 958-963.
81. Czaja, A.J.; Carpenter, H.A. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig. Dis. Sci., 2006, 51 (5), 968-975.
82. Bacon, B.R.; Treuhaft, W.H.; Goodman, A.M. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch. Intern. Med., 1981, 141 (2), 223-226.
83. Ben Ari, Z.; Mehta, A.; Lennard, L.; Burroughs, A.K. Azathioprineinduced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J. Hepatol., 1995, 23 (3), 351-354.
84. DePinho, R.A.; Goldberg, C.S.; Lefkowitch, J.H. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatichepatocellular injury in humans. Gastroenterology, 1984, 86 (1), 162-165.
85. Dubinsky, M.C.; Vasiliauskas, E.A.; Singh, H.; Abreu, M.T.; Papadakis, K.A.; Tran, T.; Martin, P.; Vierling, J.M.; Geller, S.A.; Targan, S.R.; Poordad, F.F. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology, 2003, 125 (2), 298-303.
86. de Abajo, F.J.; Montero, D.; Madurga, M.; Garcia Rodriguez, L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol., 2004, 58 (1), 71-80.
87. Dubinsky, M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol., 2004, 2 (9), 731-743.
88. Thomas, C.W.; Myhre, G.M.; Tschumper, R.; Sreekumar, R.; Jelinek, D.; McKean, D.J.; Lipsky, J.J.; Sandborn, W.J.; Egan, L.J. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther., 2005, 312 (2), 537-545.
89. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P.R.; Ahmadian, M.R.; Neurath, M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest., 2003, 111 (8), 1133-1145.
90. de Boer, N.K.; van Bodegraven, A.A.; Jharap, B.; de Graaf, P.; Mulder, C.J. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol., 2007, 4 (12), 686-694.
91. Mudter, J.; Neurath, M.F. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut, 2007, 56 (2), 293-303.
92. Steel, A.W.; Mela, C.M.; Lindsay, J.O.; Gazzard, B.G.; Goodier, M.R. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment. Pharmacol. Ther., 2011, 33 (1), 115-126.
93. Bullingham, R.E.; Nicholls, A.J.; Kamm, B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet., 1998, 34 (6), 429-455.
94. Allison, A.C.; Eugui, E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 2000, 47 (2-3), 85-118.
95. Allison, A.C. Mechanisms of action of mycophenolate mofetil. Lupus, 2005, 14 (Suppl 1), s2-8.
96. Filler, G.; Bendrick-Peart, J.; Christians, U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther. Drug Monit., 2008, 30 (2), 138-142.
97. Villarroel, M.C.; Hidalgo, M.; Jimeno, A. Mycophenolate mofetil: An update. Drugs Today (Barc.), 2009, 45 (7), 521-532.
98. Shin, M.; Moon, J.I.; Kim, J.M.; Choi, G.S.; Kwon, C.H.; Kim, S.J.; Joh, J.W.; Lee, S.K.; Lee, S.T.; Jung, H.; Lee, S.Y. Pharmacokinetics of mycophenolic acid in living donor liver transplantation. Transplant. Proc., 2010, 42 (3), 846-853.
99. Zachou, K.; Gatselis, N.; Papadamou, G.; Rigopoulou, E.I.; Dalekos, G.N. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J. Hepatol., 2011, 55 (3), 636-646.
100. Hennes, E.M.; Oo, Y.H.; Schramm, C.; Denzer, U.; Buggisch, P.; Wiegard, C.; Kanzler, S.; Schuchmann, M.; Boecher, W.; Galle, P.R.; Adams, D.H.; Lohse, A.W. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am. J. Gastroenterol., 2008, 103 (12), 3063-3070.
101. Sharzehi, K.; Huang, M.A.; Schreibman, I.R.; Brown, K.A. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can. J. Gastroenterol., 2010, 24 (10), 588-592.
102. Baven-Pronk, A.M.; Coenraad, M.J.; van Buuren, H.R.; de Man, R.A.; van Erpecum, K.J.; Lamers, M.M.; Drenth, J.P.; van den Berg, A.P.; Beuers, U.H.; den Ouden, J.; Koek, G.H.; van Nieuwkerk, C.M.; Bouma, G.; Brouwer, J.T.; van Hoek, B. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment. Pharmacol. Ther. 2011, 34 (3), 335-343.
103. Chatur, N.; Ramji, A.; Bain, V.G.; Ma, M.M.; Marotta, P.J.; Ghent, C.N.; Lilly, L.B.; Heathcote, E.J.; Deschenes, M.; Lee, S.S.; Steinbrecher, U.P.; Yoshida, E.M. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int., 2005, 25 (4), 723-727.
104. Inductivo-Yu, I.; Adams, A.; Gish, R.G.; Wakil, A.; Bzowej, N.H.; Frederick, R.T.; Bonacini, M. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin. Gastroenterol. Hepatol., 2007, 5 (7), 799-802.
105. Hlivko, J.T.; Shiffman, M.L.; Stravitz, R.T.; Luketic, V.A.; Sanyal, A.J.; Fuchs, M.; Sterling, R.K. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin. Gastroenterol. Hepatol., 2008, 6 (9), 1036-1040.
106. Aw, M.M.; Dhawan, A.; Samyn, M.; Bargiota, A.; Mieli-Vergani, G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J. Hepatol., 2009, 51 (1), 156-160.
107. Wolf, D.C.; Bojito, L.; Facciuto, M.; Lebovics, E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig. Dis. Sci., 2009, 54 (11), 2519-2522.
108. Seikaly, M.G. Mycophenolate mofetil--is it worth the cost? The infavor opinion. Pediatr. Transplant., 1999, 3 (1), 79-82.
109. McFarlane, I.G. Pathogenesis of autoimmune hepatitis. Biomed. Pharmacother., 1999, 53 (5-6), 255-263.
110. Czaja, A.J. Understanding the pathogenesis of autoimmune hepatitis. Am. J. Gastroenterol., 2001, 96 (4), 1224-1231.
111. Czaja, A.J. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol. Dietol., 2007, 53 (1), 43-78.
112. Morath, C.; Schwenger, V.; Beimler, J.; Mehrabi, A.; Schmidt, J.; Zeier, M.; Muranyi, W. Antifibrotic actions of mycophenolic acid. Clin. Transpl., 2006, 20 Suppl 17, 25-29.
113. Stuehr, D.J. Mammalian nitric oxide synthases. Biochim. Biophys. Acta, 1999, 1411 (2-3), 217-230.
114. Czaja, A.J. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J. Hepatol., 2009, 51 (1), 8-10.
115. Richardson, P.D.; James, P.D.; Ryder, S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J. Hepatol., 2000, 33 (3), 371-375.
116. Devlin, S.M.; Swain, M.G.; Urbanski, S.J.; Burak, K.W. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can. J. Gastroenterol., 2004, 18 (5), 321-326.
117. Czaja, A.J.; Carpenter, H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J. Clin. Gastroenterol., 2005, 39 (9), 819-825.
118. Adams, B.; Lazarchick, J.; Medina, A.M.; Willner, I.R.; Neville, B.; Murphy, E.; Stuart, R.; Costa, L.J. Iatrogenic immunodeficiencyassociated lymphoproliferative disease of the Hodgkin lymphomalike variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am. J. Hematol., 2010, 85 (8), 627-629.
119. Perez-Aytes, A.; Ledo, A.; Boso, V.; Saenz, P.; Roma, E.; Poveda, J.L.; Vento, M. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am. J. Med. Genet. A., 2008, 146A (1), 1-7.
120. Anderka, M.T.; Lin, A.E.; Abuelo, D.N.; Mitchell, A.A.; Rasmussen, S.A. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am. J. Med. Genet. A., 2009, 149A (6), 1241-1248.
121. Klieger-Grossmann, C.; Chitayat, D.; Lavign, S.; Kao, K.; Garcia-Bournissen, F.; Quinn, D.; Luo, V.; Sermer, M.; Riordan, S.; Laskin, C.; Matok, I.; Gorodischer, R.; Chambers, C.; Levi, A.; Koren, G. Prenatal exposure to mycophenolate mofetil: an updated estimate. J. Obstet. Gynaecol. Can., 2010, 32 (8), 794-797.
122. Lin, A.E.; Singh, K.E.; Strauss, A.; Nguyen, S.; Rawson, K.; Kimonis, V.E. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am. J. Med. Genet. A., 2011, 155A (4), 748-756.
123. Ryrfeldt, A.; Andersson, P.; Edsbacker, S.; Tonnesson, M.; Davies, D.; Pauwels, R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. Suppl., 1982, 122, 86-95.
124. Clissold, S.P.; Heel, R.C. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs, 1984, 28 (6), 485-518.
125. Hempfling, W.; Grunhage, F.; Dilger, K.; Reichel, C.; Beuers, U.; Sauerbruch, T. Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis. Hepatology, 2003, 38 (1), 196-202.
126. Edsbacker, S.; Andersson, T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin. Pharmacokinet., 2004, 43 (12), 803-821.
127. Dilger, K.; Alberer, M.; Busch, A.; Enninger, A.; Behrens, R.; Koletzko, S.; Stern, M.; Beckmann, C.; Gleiter, C.H. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment. Pharmacol. Ther., 2006, 23 (3), 387-396.
128. Danielsson, A.; Prytz, H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther., 1994, 8 (6), 585-590.
129. Wiegand, J.; Schuler, A.; Kanzler, S.; Lohse, A.; Beuers, U.; Kreisel, W.; Spengler, U.; Koletzko, S.; Jansen, P.L.; Hochhaus, G.; Mollmann, H.W.; Prols, M.; Manns, M.P. Budesonide in previously untreated autoimmune hepatitis. Liver Int., 2005, 25 (5), 927-934.
130. Csepregi, A.; Rocken, C.; Treiber, G.; Malfertheiner, P. Budesonide induces complete remission in autoimmune hepatitis. World J. Gastroenterol., 2006, 12 (9), 1362-1366.
131. Zandieh, I.; Krygier, D.; Wong, V.; Howard, J.; Worobetz, L.; Minuk, G.; Witt-Sullivan, H.; Yoshida, E.M. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can. J. Gastroenterol., 2008, 22 (4), 388-392.
132. Manns, M.P.; Woynarowski, M.; Kreisel, W.; Lurie, Y.; Rust, C.; Zuckerman, E.; Bahr, M.J.; Gunther, R.; Hultcrantz, R.W.; Spengler, U.; Lohse, A.W.; Szalay, F.; Farkkila, M.; Prols, M.; Strassburg, C.P. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology, 2010, 139 (4), 1198-1206.
133. Snider, K.R.; Potter, T.G. Budesonide for the treatment of autoimmune hepatitis. Ann. Pharmacother., 2011, 45 (9), 1144-1150.
134. Longui, C.A.; Santos, M.C.; Formiga, C.B.; Oliveira, D.V.; Rocha, M.N.; Faria, C.D.; Kochi, C.; Monte, O. Antiproliferative and apoptotic potencies of glucocorticoids: nonconcordance with their antiinflammatory and immunosuppressive properties. Arq. Bras. Endocrinol. Metabol., 2005, 49 (3), 378-383.
135. McKay, D.M.; Brattsand, R.; Wieslander, E.; Fung, M.; Croitoru, K.; Perdue, M.H. Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. J. Pharmacol. Exp. Ther., 1996, 277 (1), 403-410.
136. Strandberg, K.; Blidberg, K.; Sahlander, K.; Palmberg, L.; Larsson, K. Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm. Pharmacol. Ther., 2010, 23 (4), 316-323.
137. Efe, C.; Ozaslan, E.; Kav, T.; Purnak, T.; Shorbagi, A.; Ozkayar, O.; Berlot, A.H.; Sokmensuer, C.; Muratori, P. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun. Rev., 2011, [Epub ahead of print].
138. Geier, A.; Gartung, C.; Dietrich, C.G.; Wasmuth, H.E.; Reinartz, P.; Matern, S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol., 2003, 9 (12), 2681-2685.
139. Czaja, A.J.; Lindor, K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology, 2000, 119 (5), 1312-1316.
140. Lohse, A.W.; Gil, H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J. Hepatol., 2011, 54 (4), 837-839.
141. Czaja, A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int., 2009, 29 (6), 816-823.
142. Mederacke, I.; Helfritz, F.; Puls, F.; Ringe, K.I.; Klempnauer, J.; Manns, M.P.; Strassburg, C.P. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann. Hepatol., 2012, 11 (1), 143-144.
143. Fernandes, N.F.; Redeker, A.G.; Vierling, J.M.; Villamil, F.G.; Fong, T.L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol., 1999, 94 (1), 241-248.
144. Jackson, L.D.; Song, E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut, 1995, 36 (3), 459-461.
145. Aqel, B.A.; Machicao, V.; Rosser, B.; Satyanarayana, R.; Harnois, D.M.; Dickson, R.C. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J. Clin. Gastroenterol., 2004, 38 (9), 805-809.
146. Cuarterolo, M.L.; Ciocca, M.E.; Lopez, S.I.; de Davila, M.T.; Alvarez, F. Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis. Clin. Gastroenterol. Hepatol., 2011, 9 (2), 145-149.
147. Larsen, F.S.; Vainer, B.; Eefsen, M.; Bjerring, P.N.; Adel Hansen, B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol., 2007, 13 (23), 3232-3236.
148. Neuberger, J. Transplantation for autoimmune hepatitis. Semin. Liver Dis., 2002, 22 (4), 379-386.
149. Alvarez, F.; Ciocca, M.; Canero-Velasco, C.; Ramonet, M.; de Davila, M.T.; Cuarterolo, M.; Gonzalez, T.; Jara-Vega, P.; Camarena, C.; Brochu, P.; Drut, R.; Alvarez, E. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J. Hepatol., 1999, 30 (2), 222-227.
150. Cuarterolo, M.; Ciocca, M.; Velasco, C.C.; Ramonet, M.; Gonzalez, T.; Lopez, S.; Garsd, A.; Alvarez, F. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J. Pediatr. Gastroenterol. Nutr., 2006, 43 (5), 635-639.
151. Malekzadeh, R.; Nasseri-Moghaddam, S.; Kaviani, M.J.; Taheri, H.; Kamalian, N.; Sotoudeh, M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig. Dis. Sci., 2001, 46 (6), 1321-1327.
152. Hyams, J.S.; Ballow, M.; Leichtner, A.M. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology, 1987, 93 (4), 890-893.
153. Person, J.L.; McHutchison, J.G.; Fong, T.L.; Redeker, A.G. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J. Clin. Gastroenterol., 1993, 17 (4), 317-320.
154. Sherman, K.E.; Narkewicz, M.; Pinto, P.C. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J. Hepatol., 1994, 21 (6), 1040-1047.
155. Debray, D.; Maggiore, G.; Girardet, J.P.; Mallet, E.; Bernard, O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J. Pediatr., 1999, 135 (1), 111-114.
156. Hayashi, M.; Keeffe, E.B.; Krams, S.M.; Martinez, O.M.; Ojogho, O.N.; So, S.K.; Garcia, G.; Imperial, J.C.; Esquivel, C.O. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl. Surg., 1998, 4 (3), 208-214.
157. Trouillot, T.E.; Shrestha, R.; Kam, I.; Wachs, M.; Everson, G.T. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg., 1999, 5 (5), 375-380.
158. Vogel, A.; Heinrich, E.; Bahr, M.J.; Rifai, K.; Flemming, P.; Melter, M.; Klempnauer, J.; Nashan, B.; Manns, M.P.; Strassburg, C.P. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant., 2004, 18 (1), 62-69.
159. Campsen, J.; Zimmerman, M.A.; Trotter, J.F.; Wachs, M.; Bak, T.; Steinberg, T.; Kaplan, M.; Wright, F.; Kam, I. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl., 2008, 14 (9), 1281-1286.
160. Christians, U.; Strom, T.; Zhang, Y.L.; Steudel, W.; Schmitz, V.; Trump, S.; Haschke, M. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther. Drug Monit., 2006, 28 (1), 39-44.
161. Wojnowski, L.; Kamdem, L.K. Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol., 2006, 2 (2), 171-182.
162. Utecht, K.N.; Hiles, J.J.; Kolesar, J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am. J. Health Syst. Pharm., 2006, 63 (23), 2340-2348.
163. Staatz, C.E.; Goodman, L.K.; Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet., 2010, 49 (3), 141-175.
164. Staatz, C.E.; Goodman, L.K.; Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin. Pharmacokinet., 2010, 49 (4), 207-221.
165. Ost, L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation, 1987, 44 (4), 533-535.
166. Dirks, N.L.; Huth, B.; Yates, C.R.; Meibohm, B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther., 2004, 42 (12), 701-718.
167. Cattaneo, D.; Perico, N.; Remuzzi, G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am. J. Transplant., 2004, 4 (3), 299-310.
168. Villamil, F.; Pollard, S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl., 2004, 10 (5), 577-583.
169. de Jonge, H.; Naesens, M.; Kuypers, D.R. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther. Drug Monit., 2009, 31 (4), 416-435.
170. Schalm, S.W.; Summerskill, W.H.; Go, V.L. Development of radioimmunoassays for prednisone and prednisolone. Application to studies of hepatic metabolism of prednisone. Mayo Clin. Proc., 1976, 51 (12), 761-766.
171. Czaja, A.J.; Bianchi, F.B.; Carpenter, H.A.; Krawitt, E.L.; Lohse, A.W.; Manns, M.P.; McFarlane, I.G.; Mieli-Vergani, G.; Toda, G.; Vergani, D.; Vierling, J.; Zeniya, M. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology, 2005, 41 (1), 207-215.
172. van Rossum, H.H.; de Fijter, J.W.; van Pelt, J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther. Drug Monit., 2010, 32 (1), 3-10.
173. Scott, L.J.; McKeage, K.; Keam, S.J.; Plosker, G.L. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs, 2003, 63 (12), 1247-1297.
174. Wu, Q.; Marescaux, C.; Wolff, V.; Jeung, M.Y.; Kessler, R.; Lauer, V.; Chen, Y. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur. Neurol., 2010, 64 (3), 169-177.
175. Toledo Perdomo, K.; Navarro Cabello, M.D.; Perez Saez, M.J.; Ramos Perez, M.J.; Aguera Morales, M.L.; Aljama Garcia, P. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation. J. Nephrol., 2012, [Epub ahead of print].
176. Fukazawa, K.; Nishida, S.; Aguina, L.; Pretto, E., Jr. Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. Ann. Transplant., 2011, 16 (3), 139-142.
177. de Boer, N.K.; van Nieuwkerk, C.M.; Aparicio Pages, M.N.; de Boer, S.Y.; Derijks, L.J.; Mulder, C.J. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol. Hepatol., 2005, 17 (4), 457-461.
178. de Boer, N.K.; de Graaf, P.; Wilhelm, A.J.; Mulder, C.J.; van Bodegraven, A.A. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment. Pharmacol. Ther., 2005, 22 (5), 447-451.
179. Chan, G.L.; Erdmann, G.R.; Gruber, S.A.; Stock, P.; Chen, S.; Ascher, N.L.; Canafax, D.M. Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur J Clin Pharmacol, 1989, 36 (3), 265-271.
180. Bergan, S.; Rugstad, H.E.; Bentdal, O.; Endresen, L.; Stokke, O. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther. Drug Monit., 1994, 16 (1), 13-20.
181. Geller, S.A.; Dubinsky, M.C.; Poordad, F.F.; Vasiliauskas, E.A.; Cohen, A.H.; Abreu, M.T.; Tran, T.; Martin, P.; Vierling, J.M.; Targan, S.R. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am. J. Surg. Pathol., 2004, 28 (9), 1204-1211.
182. Ferlitsch, A.; Teml, A.; Reinisch, W.; Ulbrich, G.; Wrba, F.; Homoncik, M.; Gangl, A.; Peck-Radosavljevic, M.; Vogelsang, H. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am. J. Gastroenterol., 2007, 102 (11), 2495-2503.
183. Teml, A.; Schwab, M.; Hommes, D.W.; Almer, S.; Lukas, M.; Feichtenschlager, T.; Florin, T.; Seiderer, J.; Petritsch, W.; Bokemeyer, B.; Kreisel, W.; Herrlinger, K.R.; Knoflach, P.; Bonaz, B.; Klugmann, T.; Herfarth, H.; Pedarnig, N.; Reinisch, W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien. Klin. Wochenschr., 2007, 119 (17-18), 519-526.
184. De Bruyne, R.; Portmann, B.; Samyn, M.; Bansal, S.; Knisely, A.; Mieli-Vergani, G.; Dhawan, A. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J. Hepatol., 2006, 44 (2), 407-410.
185. Vora, A.; Mitchell, C.D.; Lennard, L.; Eden, T.O.; Kinsey, S.E.; Lilleyman, J.; Richards, S.M. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet, 2006, 368 (9544), 1339-1348.
186. Gilissen, L.P.; Derijks, L.J.; Driessen, A.; Bos, L.P.; Hooymans, P.M.; Stockbrugger, R.W.; Engels, L.G. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig. Liver Dis., 2007, 39 (2), 156-159.
187. Ansari, A.; Elliott, T.; Fong, F.; Arenas-Hernandez, M.; Rottenberg, G.; Portmann, B.; Lucas, S.; Marinaki, A.; Sanderson, J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis., 2008, 14 (10), 1399-1405.
188. de Boer, N.K.; Zondervan, P.E.; Gilissen, L.P.; den Hartog, G.; Westerveld, B.D.; Derijks, L.J.; Bloemena, E.; Engels, L.G.; van Bodegraven, A.A.; Mulder, C.J. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis., 2008, 40 (2), 108-113.
189. van Asseldonk, D.P.; Jharap, B.; Kuik, D.J.; de Boer, N.K.; Westerveld, B.D.; Russel, M.G.; Kubben, F.J.; van Bodegraven, A.A.; Mulder, C.J. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig. Liver Dis., 2011, 43 (2), 110-115.
190. van Asseldonk, D.P.; Seinen, M.L.; de Boer, N.K.; van Bodegraven, A.A.; Mulder, C.J. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. J. Crohns Colitis, 2012, 6 (1), 95-101.
191. de Boer, N.K.; Reinisch, W.; Teml, A.; van Bodegraven, A.A.; Schwab, M.; Lukas, M.; Ochsenkuhn, T.; Petritsch, W.; Knoflach, P.; Almer, S.; van der Merwe, S.W.; Herrlinger, K.R.; Seiderer, J.; Vogelsang, H.; Mulder, C.J. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion, 2006, 73 (1), 25-31.
192. Seinen, M.L.; van Asseldonk, D.P.; Mulder, C.J.; de Boer, N.K. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J. Gastrointestin. Liver Dis., 2010, 19 (3), 291-294.
193. Wusk, B.; Kullak-Ublick, G.A.; Rammert, C.; von Eckardstein, A.; Fried, M.; Rentsch, K.M. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol., 2004, 16 (12), 1407-1413.
194. Ferucci, E.D.; Hurlburt, K.J.; Mayo, M.J.; Livingston, S.; Deubner, H.; Gove, J.; Plotnik, J.; McMahon, B.J. Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. Can. J. Gastroenterol., 2011, 25 (1), 21-27.
195. Burkhart, C.; Heusser, C.; Morris, R.E.; Raulf, F.; Weckbecker, G.; Weitz-Schmidt, G.; Welzenbach, K. Pharmacodynamics in the development of new immunosuppressive drugs. Ther. Drug Monit., 2004, 26 (6), 588-592.
196. Brown, E.J.; Albers, M.W.; Shin, T.B.; Ichikawa, K.; Keith, C.T.; Lane, W.S.; Schreiber, S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature, 1994, 369 (6483), 756-758.
197. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev., 2004, 18 (16), 1926-1945.
198. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell, 2006, 124 (3), 471-484.
199. Yellen, P.; Saqcena, M.; Salloum, D.; Feng, J.; Preda, A.; Xu, L.; Rodrik-Outmezguine, V.; Foster, D.A. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle, 2011, 10 (22), 3948-3956.
200. Vemulapalli, S.; Mita, A.; Alvarado, Y.; Sankhala, K.; Mita, M. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target. Oncol., 2011, 6 (1), 29-39.
201. Marzec, M.; Liu, X.; Wysocka, M.; Rook, A.H.; Odum, N.; Wasik, M.A. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS One, 2011, 6 (9), e24849.
202. Wagner, F.; Henningsen, B.; Lederer, C.; Eichenmuller, M.; Godeke, J.; Muller-Hocker, J.; Schweinitz, D.V.; Kappler, R. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients. Eur. J. Cancer, 2012.
203. Choi, S.J.; You, H.S.; Chung, S.Y. Rapamycin-induced cytotoxic signal transduction pathway. Transplant. Proc., 2008, 40 (8), 2737-2739.
204. Rust, C.; Gores, G.J. Apoptosis and liver disease. Am. J. Med., 2000, 108 (7), 567-574.
205. Bai, J.; Odin, J.A. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun. Rev., 2003, 2 (1), 36-42.
206. Zhang, Y.; Zhang, J.W.; Lv, G.Y.; Xie, S.L.; Wang, G.Y. Effects of STAT3 Gene Silencing and Rapamycin on Apoptosis in Hepatocarcinoma Cells. Int. J. Med. Sci., 2012, 9 (3), 216-224.
207. Molhoek, K.R.; McSkimming, C.C.; Olson, W.C.; Brautigan, D.L.; Slingluff, C.L., Jr. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol. Immunother., 2009, 58 (6), 867-876.
208. Nikolaeva, N.; Bemelman, F.J.; Yong, S.L.; van Lier, R.A.; ten Berge, I.J. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation, 2006, 81 (3), 445-454.
209. Strauss, L.; Whiteside, T.L.; Knights, A.; Bergmann, C.; Knuth, A.; Zippelius, A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol., 2007, 178 (1), 320-329.
210. Kerkar, N.; Dugan, C.; Rumbo, C.; Morotti, R.A.; Gondolesi, G.; Shneider, B.L.; Emre, S. Rapamycin successfully treats posttransplant autoimmune hepatitis. Am. J. Transplant., 2005, 5 (5), 1085-1089.
211. Nocera, A.; Andorno, E.; Tagliamacco, A.; Morelli, N.; Bottino, G.; Ravazzoni, F.; Casaccia, M.; Barocci, S.; Alice, S.; Santori, G.; Ghirelli, R.; Valente, U. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant. Proc., 2008, 40 (6), 1950-1952.
212. Gibelli, N.E.; Tannuri, U.; Pinho-Apezzato, M.L.; Tannuri, A.C.; Maksoud-Filho, J.G.; Andrade, W.C.; Velhote, M.C.; Santos, M.M.; Ayoub, A.A.; Marques da Silva, M. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant. Proc., 2009, 41 (3), 901-903.
213. Meiser, B.; Buchholz, S.; Kaczmarek, I. De-novo calcineurininhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results. Curr. Opin. Organ Transplant., 2011, 16 (5), 522-528.
214. Uhlmann, D.; Weber, T.; Ludwig, S.; Ludwig, B.; Bartels, M.; Hauss, J.; Jonas, S.; Witzigmann, H. Long-term outcome of conversion to sirolimus monotherapy after liver transplant. Exp. Clin. Transplant., 2012, 10 (1), 30-38.
215. Pham, P.T.; Pham, P.C.; Danovitch, G.M.; Ross, D.J.; Gritsch, H.A.; Kendrick, E.A.; Singer, J.; Shah, T.; Wilkinson, A.H. Sirolimusassociated pulmonary toxicity. Transplantation, 2004, 77 (8), 1215-1220.
216. Roberts, R.J.; Wells, A.C.; Unitt, E.; Griffiths, M.; Tasker, A.D.; Allison, M.E.; Bradley, J.A.; Watson, C.J. Sirolimus-induced pneumonitis following liver transplantation. Liver Transpl., 2007, 13 (6), 853-856.
217. Morcos, A.; Nair, S.; Keane, M.P.; McElvaney, N.G.; McCormick, P.A. Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus. Ir. J. Med. Sci., 2012.
218. Veroux, M.; Tallarita, T.; Corona, D.; D'Assoro, A.; Gurrieri, C.; Veroux, P. Sirolimus in solid organ transplantation: current therapies and new frontiers. Immunotherapy, 2011, 3 (12), 1487-1497.
219. Gomez-Fernandez, C.; Garden, B.C.; Wu, S.; Feldman, D.R.; Lacouture, M.E. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur. J. Cancer, 2012, 48 (3), 340-346.
220. Czaja, A.J. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis., 2002, 6 (3), 799-824.
221. Czaja, A.J.; Freese, D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology, 2002, 36 (2), 479-497.
222. Cross, T.J.; Antoniades, C.G.; Muiesan, P.; Al-Chalabi, T.; Aluvihare, V.; Agarwal, K.; Portmann, B.C.; Rela, M.; Heaton, N.D.; O'Grady, J.G.; Heneghan, M.A. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl., 2007, 13 (10), 1382-1388.
223. Sanchez-Urdazpal, L.; Czaja, A.J.; van Hoek, B.; Krom, R.A.; Wiesner, R.H. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology, 1992, 15 (2), 215-221.